Yes, Eliquis (apixaban) is FDA-approved for DVT prophylaxis, but only in a specific context: preventing deep vein thrombosis in adults who have undergone hip or knee replacement surgery. It is not approved as a general-purpose blood clot preventive for other surgical procedures, hospitalized medical patients, or long-distance travel.
How Eliquis Prevents Blood Clots
Eliquis works by selectively blocking a clotting protein called Factor Xa, which plays a central role in the chain reaction that forms blood clots. By shutting down this protein, Eliquis reduces the body’s ability to generate thrombin, the enzyme that ultimately turns liquid blood into a solid clot. Unlike older blood thinners, it doesn’t need any helper proteins in your blood to do its job, and it can neutralize Factor Xa even when it’s already embedded inside an existing clot.
This mechanism makes it well suited for post-surgical situations where blood flow slows down in the legs and the risk of clot formation spikes. Hip and knee replacements are particularly high-risk because of the combination of immobility, tissue trauma, and changes to blood flow in the lower extremities.
Which Surgeries Qualify
The FDA indication is narrow. Eliquis is approved for DVT prophylaxis after total hip replacement and total knee replacement in adults. These are the only surgical scenarios where it carries this specific label. Other approved uses for Eliquis exist (treating existing DVTs, preventing stroke in atrial fibrillation, reducing recurrence of blood clots), but those are separate indications with different dosing.
Some surgeons and hospitalists prescribe Eliquis off-label for clot prevention in other situations, such as after abdominal surgery or during cancer treatment. A phase II trial in patients with metastatic cancer found a major bleeding rate of about 2.2% among those taking apixaban for clot prevention, with no fatal bleeds. But off-label use is a clinical judgment call, not a standard recommendation.
What the Clinical Trials Showed
Eliquis earned its approval largely through the ADVANCE series of clinical trials, which compared it head-to-head against enoxaparin (a standard injectable blood thinner given after joint replacement). In ADVANCE-1, which studied patients after total knee replacement, Eliquis 2.5 mg taken twice daily was compared to enoxaparin injections given every 12 hours.
The primary outcome, a composite of DVT detected on imaging, confirmed symptomatic DVT or pulmonary embolism, and death from any cause, occurred in 9.0% of patients on Eliquis versus 8.9% on enoxaparin. The rates were nearly identical, though the trial technically did not meet its pre-specified statistical threshold for non-inferiority. The reason was somewhat unusual: the enoxaparin group had a lower-than-expected event rate, which made the study underpowered to detect the difference it was designed to find, even though the two drugs performed almost identically in practice.
Later trials in the ADVANCE program provided stronger statistical support, particularly for hip replacement, and collectively formed the basis for FDA approval. The key takeaway for patients is that Eliquis performed comparably to injectable blood thinners but with a significant practical advantage: it’s a pill, not a shot.
How Long You Take It
The duration of prophylaxis differs depending on the joint replaced. For knee replacement, the typical course is 10 to 14 days. For hip replacement, it extends to 35 days, reflecting the longer window of elevated clot risk after hip surgery. Your surgeon will specify the exact timeline. The standard prophylactic dose is 2.5 mg twice daily, which is lower than the doses used for treating an active blood clot or preventing stroke.
You generally start taking Eliquis 12 to 24 hours after surgery, once surgical bleeding is under control. Missing doses or stopping early increases your risk of developing a clot, so consistency matters during the full treatment window.
Bleeding Risk and Safety
The main concern with any blood thinner used for clot prevention is bleeding. In the ADVANCE trials, Eliquis showed bleeding rates that were comparable to or lower than enoxaparin. Because the prophylactic dose (2.5 mg twice daily) is smaller than therapeutic doses, the bleeding risk is relatively modest for most patients.
That said, certain situations increase your bleeding risk. Active bleeding from any source is an absolute contraindication. If you have severe kidney impairment, the drug has not been well studied, though no formal dose adjustment is recommended for the prophylaxis indication. Patients on dialysis or with very low kidney function (creatinine clearance below 15 mL/min) fall into an evidence gap where the data is limited to lab-based modeling rather than real clinical trials.
Why Eliquis Over Injections
Before drugs like Eliquis, the standard for post-surgical clot prevention was injectable blood thinners. Patients either received shots in the hospital or learned to self-inject at home, which many found unpleasant and difficult to manage. Eliquis offered a comparable level of protection in pill form, which simplified the post-surgical recovery process considerably.
The convenience factor is not trivial. Studies consistently show that patients are more likely to complete the full course of a medication they can swallow than one they have to inject. For a condition where skipping doses directly raises the risk of a potentially life-threatening clot, that compliance advantage translates into a real clinical benefit.